LYSOGENE Business Summary
The company now has 2 drug candidates in clinical development of which 1 in phase 2/3 (LYS-SAF302 for the treatment of Sanfilippo syndrome type A) and 1 in phase 1/2 (LYS-GM101 for the treatment of GM1 gangliosidosis).
Number of employees: 22
Managers
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 52 | 01/09/01 | |
| Director of Finance/CFO | - | 01/20/01 | |
Marie Trad
CTO | Chief Tech/Sci/R&D Officer | - | 01/22/01 |
Ralph Laufer
CTO | Chief Tech/Sci/R&D Officer | - | 02/18/02 |
Marie Deneux
PRN | Corporate Officer/Principal | - | - |
Members of the board
| Members of the board | Title | Age | Since |
|---|---|---|---|
Peter Lichtlen
BRD | Director/Board Member | 56 | 01/18/01 |
Michel Picot
BRD | Director/Board Member | 72 | - |
| Chief Executive Officer | 52 | 01/09/01 | |
Carole Deffez
BRD | Director/Board Member | - | 26/19/26 |
Céline Fantin
BRD | Director/Board Member | - | - |
Share class
| Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
|---|---|---|---|---|---|
| Stock A | 1 | 17,811,140 | 12,983,653 ( 72.90 %) | 13,156 ( 0.0739 %) | 72.90 % |
Company contact information
Lysogene SA
18-20, rue Jacques Dulud Neuilly-sur-Seine
92200, Paris
+33 1 41 43 03 90
http://www.lysogene.com
Sector
| 1st Jan change | Capi. | |
|---|---|---|
| -20.45% | 10.82B | |
| +43.17% | 3.25B | |
| -35.86% | 2.11B | |
| -17.21% | 2.08B | |
| -29.81% | 1.48B | |
| +17.56% | 1.02B | |
| -4.37% | 733M | |
| -37.00% | 391M | |
| -46.94% | 383M |
